Moderna announces first participant dosed in phase 3 study of mrna-1083, a combination vaccine against influenza and covid-19

Mrna-1083 is moderna's first respiratory combination vaccine candidate to enter a phase 3 trial phase 3 initiation follows data from a phase 1/2 trial where mrna-1083 showed strong immunogenicity against influenza and covid-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines company has multiple programs in phase 3 development across several areas, including respiratory diseases, latent viruses, and oncology cambridge, ma / accesswire / october 24, 2023 / moderna, inc. (nasdaq:mrna) today announced that the first participant has been dosed in a phase 3 study of the company's combination vaccine candidate against influenza and covid-19 (mrna-1083) in the u.s. the trial is expected to enroll approximately 8,000 adults in the northern hemisphere. the phase 3 study will evaluate the immunogenicity, safety, and reactogenicity of mrna‐1083 as compared with active control, co‐administered licensed influenza and sar‐cov‐2 vaccines in two independent age‐group sub‐study cohorts involving 4,000 adults 65 years and older and 4,000 adults 50 to
MRNA Ratings Summary
MRNA Quant Ranking